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Recently, the state of oligometastases has been spotlighted in the treatment strategy for metastases.
Aggressive local treatment for oligometastases, including pulmonary resection, stereotactic body
radiotherapy (SBRT), radiofrequency ablation, and cryoablation has been the subject of research.
Among studies on the local treatment, those on SBRT more often evaluated local control as the
primary outcome, and those on pulmonary metastasectomy more often evaluated overall survival as
the primary outcome. Oligometastases is a disease concept that is deﬁned by a state of limited
systemic metastatic tumors for which local ablative therapy could be curative. By deﬁnition, the
purpose of local treatment for oligometastases is cure, and the primary outcome to be analyzed
should be disease-free survival. As systemic adjuvant therapy in addition to local treatment with
complete ablation has some effect on micrometastases, in clinical research on oligometastases, the
only treatment modality under evaluation should be local ablation. There are multiple discrete
indications for the local treatment of metastatic lesions. The purposes of these indications are (a) the
intent to cure oligometastases, (b) the intent to prolong survival as a part of multidisciplinary
therapy, and (c) local control for palliative care. In order to appropriately evaluate the signiﬁcance of
local treatment, the outcomes should depend on the indication for treatment. The corresponding
outcomes to consider are (a) disease-free survival, (b) overall survival, and (c) local control. Factorial
analysis of each outcome corresponding to each indication for local therapy would yield information
on each clinical presentation to help decide treatment.
& 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/)..01.001
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In general, metastatic malignancies are associated with a
poor prognosis, and systemic chemotherapy and molecular
targeted therapy are the standards of treatment [1–4]. With
the exception of histologic types that are very sensitive to
chemotherapy, most solid tumors in the metastatic state are
rarely curative and those patients ultimately die of theiren access article under the CC BY-NC-ND license
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spotlighted in the treatment strategy for metastases [5–7].
Aggressive local treatment for oligometastases, including
pulmonary resection, stereotactic body radiotherapy (SBRT),
radiofrequency ablation [8], and cryoablation [9]—either
alone or combined with systemic chemotherapy—has been
the subject of research [6,7].
Currently, SBRT is indicated in patients who are consid-
ered nonsurgical candidates; however, the administration of
SBRT has rapidly become a widely adopted treatment
modality [7,10]. SBRT results in minimal morbidity and
provides high local control rates for medically inoperable
stage I non-small cell lung cancer [11]. Several studies have
evaluated SBRT for pulmonary metastases, for example
from colorectal cancer [12]. Table 1 shows recent repre-
sentative studies of local treatment for colorectal cancer.
In deciding local treatment, oligometastases is more often
considered an indication for SBRT than pulmonary metasta-
sectomy. Recent SBRT research commonly refers to oligo-
metastases in the discussion of treatment indications [7].
More recently, the state of oligometastases has been discussed
in pulmonary metastasectomy [6,13].
Despite an increasing interest in oligometastases, the
deﬁnition of the term “oligometastases” can be very con-
fusing because it has been dependent on the particular
research. Many researchers have deﬁned oligometastases as
metastases that are limited in both number (typically, less
than 5) and location. Another confusing issue is outcome
evaluation; researchers have evaluated the outcome of
oligometastases by overall survival or local control. InTable 1 Recently published studies of local treatment and ou
Author, year Study design Treatment indicatio
Inoue, 2013 [32] Retro Not described
Widder, 2013 [33] Retro Oligometastases
Duncker-Rohr, 2013 [34] Retro r 5 cm diameter
Takeda, 2011 [35] Retro Oligometastases
Kim, 2009 [36] Retro Isolated metastases
Rusthoven, 2009 [37] Pros (phase I/II) 1–3 metastases and
McCammon, 2009 [38] Retro Not described
Norihisa, 2008 [39] Retro Oligometastases
Milano, 2008 [40] Retro Oligometastases (5
Renaud, 2014 [41] Retro Traditional criteria
Embun, 2013 [42] Retro Not described
Iida, 2013 [43] Retro Not described
Treasure, 2012 [44] Pros Traditional criteria
Blackmon, 2012 [45] Retro Not described
Chao, 2012 [46] Retro Not described
Hamaji, 2012 [47] Retro Not described
Borasio, 2011 [48] Retro Traditional criteria
Riquet, 2010 [49] Retro Traditional criteria
Hwang, 2010 [50] Retro Traditional criteria
Onaitis, 2009 [30] Retro Not described
Watanabe, 2009 [51] Retro Traditional criteria
Traditional criteria: representative term for criteria proposed in the
SBRT: stereotactic body radiation therapy; OS: overall survival; LC: lo
free survival.
aNumber of SBRT cases is shown as number of cases of colorectalprevious reports of local treatment for colorectal cancer,
regardless of whether the indication for treatment was
oligometastases, reports on SBRT more often evaluated local
control as the primary outcome, and reports on pulmonary
metastasectomy more often evaluated overall survival as the
primary outcome (Table 1). Due to the confusing deﬁnitions,
treatment indications, and outcome evaluation for oligome-
tastases, improper discussions and conclusions result when
attempting to link published evidence to clinical practice.
Here, we review oligometastases and other indications for
local treatment, and we discuss adequate outcome measures
for future trials.2. Original concept of oligometastases
Hellman and Weichselbaum originally proposed the state of
oligometastases in 1995 based on a consideration of the
multistep nature of cancer progression [5]. They proposed
the existence of an oligometastatic state that was an
“intermediate between purely localized lesions and those
widely metastatic” [5]. The state was expounded to be
“amenable to a curative therapeutic strategy” and “amen-
able to localized therapy” [5]. This concept is very attrac-
tive and realistic; in actual clinical practice, when clinicians
decide to perform local treatment such as pulmonary
resection for metastatic tumors, they presume curability
to some extent. Many recent studies of local ablation for
metastatic malignancies actually refer to the concept of the
oligometastatic state in their discussions [6,7,13]. As sometcomes for metastatic colorectal cancer.
n Treatment (no. of cases)a Outcome evaluated
SBRT (37/87 patients) OS, LC
Metastasectomy (68)
SBRT (31/42 patients)
Primary: OS
Secondary: PFS, LC
SBRT (8/39 patients) LC, OS
SBRT (15/34 patients) LC
SBRT (13 patients) OS, LC, PFS
o7 cm SBRT (9/38 patients) LC, OS
SBRT (?/165 lesions) LC
SBRT (9/34 patients) OS, LC, PFS
or fewer) SBRT (?/103 lesions) LC
Metastasectomy (320) OS
Metastasectomy (543) Not shown
Metastasectomy (1030) OS
Metastasectomy Not shown
Metastasectomy (229) OS, RFS
Metastasectomy (143) OS, recurrence rate
Metastasectomy (518) OS
Metastasectomy (137) OS
Metastasectomy (127) OS
Metastasectomy (125) OS, LC
Metastasectomy (378) OS, RFS
Metastasectomy (113) OS, LC
era from 1960s to 1980s.Retro: retrospective; Pros: prospective;
cal control; PFS: progression-free survival; and RFS: recurrence-
cancer divided by number of cases of all other cancers.
3Oligometastases: Deﬁned by prognosis and evaluated by cureresearchers have noted, it seems plausible that oligometas-
tases are limited metastatic tumors that could be cured
with local treatment [14].
The distinguishing characteristic of oligometastases is based
on the concept of curability as the outcome. With this
approach, a correct diagnosis of oligometastases is only con-
ﬁrmed once it has been determined whether the patient is
cured. Therefore, the term “oligometastases” does not simply
represent a clinical appearance at the time of treatment
decision-making but instead includes the outcome of curability
with local ablation. By deﬁnition, the purpose of local treat-
ment for oligometastases is cure rather than the prolongation of
survival, the decrease in tumor volume, or palliative care.
Therefore, in order to identify the clinical appearance sugges-
tive of oligometastases at the time of decision-making, a
retrospective factorial analysis for oligometastases focusing on
the outcomes of cure would be necessary.3. Pulmonary metastasectomy
In the pre-SBRT era, the treatment with a curative intent
for metastatic tumors in the lung and liver was surgical
resection. Pulmonary metastasectomy has been a commonly
performed surgery. One of the most frequently reported
tumors for pulmonary metastasectomy is colorectal cancer.
In current practice, pulmonary resection for metastatic
tumors from colorectal cancer is advocated based on
numerous retrospective reports, despite the fact that the
effectiveness of this procedure remains unclear due to a
lack of randomized controlled trials [13]. A recent systema-
tic review and meta-analysis showed that overall survival
ranged from 27% to 68% after pulmonary resection of
metastases [15]. Multifactorial analysis for overall survival
revealed some risk factors for poor overall survival, includ-
ing short disease-free interval, multiple lesions, and ele-
vated prethoracotomy CEA.
From the 1960s to the 1980s, multiple expert groups
proposed indications for the surgical resection of metastatic
tumors [16–18]. These criteria were very similar, and most
clinicians accepted and followed them in clinical practice.
In 1965, the original criteria proposed by Thomford et al.
[16] were: (1) the patient must have a good risk for surgical
intervention, (2) the primary malignancy is controlled,
(3) there is no evidence of metastatic disease elsewhere
in the body, and (4) roentgenologic evidence of pulmonary
metastasis is limited to one lung. The criteria (3) and
(4) above are now modiﬁed as follows: (3) no extrapulmon-
ary metastasis exists or, if present, metastasis can be
controlled by surgery or other modalities, and (4) pulmonary
metastases are thought to be completely resectable [19].
Likewise, Martini and McCormack et al. [17,20] and Moun-
tain et al. [18] reported similar criteria based on their
experiences. Among all criteria, two are consistent between
researchers—controlled primary tumor and no extrapulmon-
ary lesion—and are considered to represent the clinical
appearance of developing tumors at the time of treatment
decision-making. The tumor situation described by these
criteria appears similar to that of an oligometastatic state.
However, the Thomford criteria do not take into account
prognosis, whereas the concept of oligometastases includes
the prognosis of cure.In research studies, pulmonary metastasectomy has been
primarily evaluated by overall survival. Overall survival
represents the entire duration of various treatments,
including local ablation, and does not depend on cure but
rather on length of time that patients are alive. In the case
of colorectal cancer, development of new agents such as
irinotecan, oxaliplatin, and biologic agents targeting either
epidermal growth factor receptor or vascular endothelial
growth factor have greatly prolonged overall survival since
the late 1990s [21,22]. Adjuvant chemotherapy after metas-
tasectomy for liver and lung metastases from colorectal
cancer has been shown to have a signiﬁcant survival beneﬁt
[23]. To effectively prolong overall survival, multidisciplin-
ary therapy is superior for metastatic disease [24,25]. In this
approach, the goal of local treatment might not necessarily
be cure, and a decrease of tumor volume might be
acceptable for the purpose of treatment. Although there
is an opinion that prolonged survival due to improved
systemic chemotherapy increases chance of local treat-
ment, the signiﬁcance of pulmonary metastasectomy itself
on overall survival in multidisciplinary therapy becomes
ambiguous. The indication for pulmonary metastasectomy
to prolong overall survival remains an unresolved issue that
necessarily requires a randomized prospective study, but in
the era of quick-paced drug development, it is considered
almost impossible to identify the signiﬁcance of the local
therapy in any analysis of overall survival.
4. Treatment for oligometastases
For various malignancies, systemic chemotherapy and mole-
cular targeted therapy have been proven to be effective for
metastatic disease and are considered a standard treat-
ment strategy. In the clinical setting, when local treatment
achieves complete resection or complete ablation, the
addition of systemic chemotherapy has tended to yield a
favorable outcome [23,26,27]. Systemic treatment has a
proven effect on systemic metastatic disease, most likely
even on lesions that have not appeared as clinical physio-
logical ﬁndings. As noted above, oligometastases are limited
metastatic tumors that might be cured with local treat-
ment. From a pathophysiological perspective, the oligome-
tastatic state denies the existence of micrometastases,
which are too small to be detected. Systemic adjuvant
therapy in addition to local treatment with complete
ablation has some effect on micrometastases and would
obscure the signiﬁcance of the local treatment. In order to
evaluate the correctness of the clinical decision-making in
diagnosing the oligometastatic state, local treatment alone
for oligometastases, not combined with systemic treatment,
would reveal the signiﬁcance of local treatment on the
outcome of cure. With that in mind, the treatment modality
for clinical research on oligometastases should only be local
ablation, or variations in systemic therapy should be mini-
mized or controlled for where possible.
5. Evaluation of oligometastases
There is controversy over the existence of an oligometa-
static state [28,29]. Although it is very difﬁcult strictly to
verify the existence of an oligometastatic state using the
Table 2 Indications for local treatment: differences between the Thomford criteria and oligometastases.
Thomford criteria Oligometastases
Deﬁnition (1) Tolerable risks
(2) Controlled primary tumor
(3) No extrapulmonary lesion
(4) Limited to one lung
Limited metastatic tumors that could be cured with
local treatment
Representation of the above
deﬁnition
Clinical appearance of tumor and
surgical tolerability
Concept with a prognostic reference
Purpose of treatment Prolonged survival Cure
Outcome to evaluate Overall survival Disease-free survival
Table 3 Multiple indications for the local treatment of metastatic disease and corresponding outcomes to evaluate.
Objective Oligometastases Limited clinical appearance of
metastatic tumors
Symptomatic or potentially symptomatic
local tumors
Purpose of treatment To cure To prolong survival Palliative care
Role of local
treatment
To cure To decrease tumor volume Palliative care
Treatment under
evaluation
Local therapy Multidisciplinary therapy Multidisciplinary therapy
Modality of local
treatment
Surgery or
radiotherapy
Surgery or radiotherapy Radiotherapy is superior
Outcome to evaluate Disease-free
survival
Overall survival Local control
H. Kaneda, Y. Saito4scientiﬁc method, there seems to be no doubt that a few
metastases are in mid-course of development into malig-
nant tumor. Thus, what needs to be discussed is not whether
oligometastases exist but rather, what kind of clinical
appearance represents the oligometastatic state.
Compared to the Thomford criteria [16], which judge the
indication for surgical resection simply by clinical appear-
ance, oligometastases is a concept that is deﬁned by the
prognosis of cure. This comparison is shown in Table 2. By its
precise deﬁnition, the clinical diagnosis of metastatic
tumors as oligometastases can only be made correctly at
the time when the patients are determined to be cured or
not cured. Given this perspective, the purpose of local
treatment for oligometastases is to cure patients, rather
than decrease tumor volume, prolong survival, or alleviate
patients' symptom. Therefore, in clinical research, which
evaluates the treatment of oligometastases, the primary
outcome to be analyzed should be disease-free survival,
which is deﬁned by no recurrence, rather than overall
survival, which is deﬁned regardless of recurrence.
Most previous clinical research of local ablation for
metastatic disease has evaluated overall survival and local
control. A summary of recent studies of local treatment for
colorectal cancer is shown in Table 1. Even in research of
oligometastases, the evaluated outcomes were still overall
survival and local treatment [6,7,28]. Discussion regarding
the methodology in the evaluation of oligometastases is
limited [28]. In past reports of local treatment for meta-
static disease, disease-free survival has rarely been eval-
uated [14,30]; Onaitis et al. reviewed patients undergoingpulmonary resection for colorectal metastases and reported
recurrence-free survival separate from overall survival [30].
Their factorial analysis of recurrence showed that age
younger than 65 years, female, disease free interval less
than 1 year, and number of metastases greater than three,
were all risk factors for recurrence, and they also discussed
the chance for cure with pulmonary resection of metastases.
Aside from disease-free survival, the proportion of patients
who have long-term disease-free survival or cure may be an
effective and appropriate evaluation for oligometastases.
Tomlinson et al. reviewed patients who had undergone
resection of colorectal liver metastases and showed that
97% of 10-year survivors were disease-free and appeared to
be cured of their disease [31]. These researchers determined
the cure rate to be at least 17% and potentially as high as
25%. The aims of their study were to deﬁne cure after
resection of colorectal liver metastases, to determine the
cure rate based on actual survivors, and to identify clinical
characteristics associated with a cured patient to improve
patient selection for surgical therapy. This approach would be
applicable for research of oligometastases.6. Indications for local therapy and
corresponding outcomes
In the past, the indication for local therapy for metastatic
malignancies has been discussed, but the relationship between
the indications and the outcomes has not been given acade-
mically rigorous consideration. Although the indications for
5Oligometastases: Deﬁned by prognosis and evaluated by curelocal therapy of metastases discussed from the 1960s to the
1980s did not explicitly include oligometastases, neither did
those indications exclude this disease state.
There are multiple discrete indications for the local
treatment of metastatic lesions, as shown in Table 3. The
purposes of these indications are (a) the intent to cure
oligometastases, (b) the intent to prolong survival as a part
of multidisciplinary therapy, and (c) palliative care. In order
to appropriately evaluate the signiﬁcance of local treat-
ment, the outcomes should depend on the indication for
treatment. The corresponding outcomes to consider are (a)
disease-free survival, (b) overall survival, and (c) local
control. Factorial analysis of each outcome corresponding
to each indication for local therapy would yield information
on each clinical presentation to help decide treatment.
7. Summary
Oligometastases is a disease concept that is deﬁned by a
state of limited systemic metastatic tumors for which local
ablative therapy could be curative. By deﬁnition, the
purpose of local treatment for oligometastases is cure,
and the primary outcome to be analyzed should be
disease-free survival. Systemic adjuvant therapy in addition
to local treatment with complete ablation has some effect
on micrometastases. In clinical research on oligometas-
tases, the only treatment modality under evaluation should
be local ablation. In order to appropriately evaluate the
signiﬁcance of local treatment, the outcomes addressed
should depend on the indication for treatment: the intent to
cure oligometastases, the intent to prolong survival as a
part of multidisciplinary therapy, and local control for
palliative care.
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